Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Next Previous
Trial Profile

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors Brooklyn ImmunoTherapeutics; Eterna Therapeutics; IRX Therapeutics

    • Most Recent Events

    • 11 Sep 2017 Results published in an IRX Therapeutics media release.
    • 11 Sep 2017 According to an IRX Therapeutics media release, results from the study have been presented at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
    • 02 Aug 2017 According to an IRX Therapeutics media release, data from this trial will be presented at at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top